SCHEMBL6038515

SCHEMBL6038515

CCc1ccc(S(=O)(=O)Nc2nccnc2OCCOc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 5/20 0.48
MAPT P10636 3/20 0.46
HTT P42858 3/20 0.45
CCR2 P41597 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
ALOX12 P18054 1/20 0.43
CACNA1B Q00975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038452 0.91 MEN1 (0.46) KMT2AL3MBTL1MEN1MAPTHTT
SCHEMBL6038562 0.88 KMT2A (0.49) KMT2AL3MBTL1MEN1MAPTHTT
SCHEMBL6038954 0.88 KMT2A (0.50) KMT2AL3MBTL1MEN1HTTCCR2
SCHEMBL6039220 0.86 MEN1 (0.53) KMT2AMEN1CCR2ALDH1A1ALOX12
SCHEMBL6039126 0.86 AR (0.50) KMT2AL3MBTL1MEN1HTTCCR2
SCHEMBL6038416 0.86 TSHR (0.51) KMT2AL3MBTL1MEN1CCR2ALDH1A1
SCHEMBL6038581 0.85 MEN1 (0.50) KMT2AL3MBTL1MEN1MAPTHTT
SCHEMBL6038549 0.84 KDM4E (0.65) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL6039119 0.84 PTGDR2 (0.52) KMT2AL3MBTL1MEN1MAPTHTT
SCHEMBL6038732 0.81 KMT2A (0.48) KMT2AL3MBTL1MEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885L3MBTL1 2666/4885MEN1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.